Supercharged t cells take on Hard-to-Treat lymphoma
NCT ID NCT00368082
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether specially trained immune cells (T cells) that are made resistant to a tumor's defense chemical can safely fight relapsed EBV-positive lymphoma. Eight patients will receive two injections of these modified cells, 14 days apart, at increasing doses. The main goal is to find the safest dose and check for side effects, while also seeing if the cells survive and shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T cells (TGFbeta-resistant LMP-specific cytotoxic T lymphocytes)
What this could lead to
If it works, this could point toward a new treatment for relapsed EBV-positive lymphoma by helping immune cells survive and attack tumors.
What could go wrong
This is a very early Phase 1 trial with only 8 participants, so it is too small to prove effectiveness. The therapy may not work or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Childrens Hospital
Houston, Texas, 77030, United States